Recurrent Brain Neoplasm Clinical Trial
Official title:
Pilot Trial of Dose-Volume Constraints for Reirradiation of Recurrent Brain Tumors
This pilot clinical trial studies the side effects and best dose of radiation therapy in patients with brain tumors that have come back after previous treatment with radiation therapy. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radiation therapy in different ways may kill more tumor cells.
PRIMARY OBJECTIVES: I. To estimate the rate of grade 3 or higher central nervous system (CNS) necrosis 6 months after reirradiation of the brain for recurrent tumor. SECONDARY OBJECTIVES: I. To evaluate acute and late toxicities of reirradiation. II. To evaluate longitudinal changes in symptom burden of patients undergoing reirradiation. III. To use Advanced Brain Tumor Imaging (ABTI) to evaluate changes in the brain after reirradiation, including progression, pseudoprogression, and radionecrosis. IV. To estimate progression-free survival (PFS) and overall survival (OS) following reirradiation. OUTLINE: Patients are assigned to 1 of 2 arms based on age. ARM I (Age 0-18 years): Patients undergo radiation therapy with conventional fractionation and dose constraints. Treatment continues for up to 6 weeks in the absence of disease progression or unacceptable toxicity. ARM II (Age > 18 years): Patients undergo radiation therapy with conventional fractionation and dose constraints. Patients also receive bevacizumab concurrently at the discretion of the treating neuro-oncologist. Treatment continues for up to 6 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 1 month, then every 2 months for 1 year, then every 3 months for 1 year. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01250470 -
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
|
Phase 1 | |
Completed |
NCT03071913 -
Blood Brain Barrier Differences in Patients With Brain Tumors Undergoing Surgery
|
||
Active, not recruiting |
NCT02389309 -
Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02323880 -
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
|
Phase 1 | |
Completed |
NCT02167204 -
18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors
|
N/A | |
Completed |
NCT02575027 -
Palliative 4pi Radiotherapy in Treating Patients With Recurrent Glioblastoma Multiforme
|
N/A | |
Recruiting |
NCT02359565 -
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
|
Phase 1 | |
Completed |
NCT01609790 -
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
|
Phase 2 | |
Completed |
NCT02661282 -
Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT02754544 -
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
|
N/A | |
Completed |
NCT01904123 -
STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain
|
Phase 1 | |
Active, not recruiting |
NCT02020720 -
18F-DOPA-PET in Planning Surgery in Patients With Gliomas
|
Early Phase 1 | |
Active, not recruiting |
NCT01503086 -
Computer Training Program for Younger Patients With a Brain Tumor Who Underwent Radiation Therapy
|
N/A | |
Active, not recruiting |
NCT02671981 -
Concurrent Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
|
Phase 2 | |
Recruiting |
NCT04588246 -
Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
|
Phase 3 | |
Completed |
NCT02658981 -
Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
|
Phase 1 | |
Withdrawn |
NCT02521090 -
EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma
|
Phase 1/Phase 2 |